Phoenix, September 22, 2025 /PRNewswire/ -Trinity Capital Inc. (NASDAQ: TRIN) (The “Company”) today announced its $45 million growth capital commitment to Rapid Micro Biosystems (NASDAQ: RPID) (“Rapid Micro”).
Rapid Micro specializes in automating microbial quality control in mission-critical applications such as environmental surveillance, water testing, fertility testing, and bioburden testing. The company's GrowthDirect® platform offers faster results, higher accuracy, greater operational efficiency, and improved data integrity, allowing faster decisions to help customers ensure a safe and consistent supply of critical, critical healthcare products.
“In an industry that cannot compromise quality, rapid microbiosystems provide the need for automation and reliability manufacturers,” said Rob Lake, senior managing director of life sciences at Trinity Capital. “They are transforming critical processes within biopharma manufacturing and are proud to partner with teams that drive meaningful impact across the industry.”
This new capital will help to expand the operation of the micro quickly, support the continued global commercial expansion of the growth direct platform, and include ongoing investments to reduce product costs, improve manufacturing efficiency, and increase total margins through service productivity.
“We're committed to providing a range of services to our customers,” said Robert Spignesi, president and CEO of Rapid Micro Biosystemss. “The facility has significantly strengthened our financial position and continues to focus on long-term revenue growth, expanding margins and increasing shareholder value.”
About Trinity Capital Inc.
Trinity Capital Inc. (NASDAQ: TRIN) is an international alternative asset manager that seeks to provide consistent returns to investors through access to private credit markets. The Trinity Capital Sources and Structure invests in capitalized, growth-oriented companies across five different lending industries: sponsored finance, equipment finance, technology lending, asset-based lending and life sciences. As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed over $4.7 billion in more than 420 investments since its founding in 2008 (as of June 30, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located throughout the US and Europe. For more information about Trinity Capital, visit trinitycapital.com and connect to the latest activities via LinkedIn and X (@Trincapital).
About the rapid microbiosystem
Rapid Micro Biosystems is an innovative life sciences technology company that provides mission-critical automation solutions to promote the efficient production and fast and safe release of medical products such as biology, vaccines, cell and gene therapy, and sterile injectables. The company's flagship growth direct system automates and modernizes outdated manual microbial quality control (“MQC”) test workflows used in the largest and most complex pharmaceutical manufacturing industries around the world. Growth Direct System brings quality control labs to the manufacturing floor, unlocking the power of MQC automation, achieving faster results, increased operational efficiency, improved data integrity regulations, and the rapid decisions customers rely on to ensure a safe and consistent supply of critical, consistent medical products. The company is headquartered in Lexington, Massachusetts, with US manufacturing in Lowell, Massachusetts and global locations in Switzerland, Germany and the Netherlands. For more information, visit www.rapidmicrobio.com or follow the company @rapidmicrobio or LinkedIn's X (formerly known as Twitter).
View original content and multimedia: https://www.prnewswire.com/news-releases/trinity-capital-inc-provides-45millin-in-howth-catital-to-rapid-micro-biosystems-modernizizing-healthcare-dustrypropics-30256.html
Source Trinity Capital Inc.
